Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 For CHB-Associated Liver Fibrosis
Portfolio Pulse from Benzinga Newsdesk
Gyre Therapeutics has completed the pivotal Phase 3 trial for F351, a treatment for CHB-associated liver fibrosis, in China. Topline data is expected by Q1 2025.
October 22, 2024 | 8:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gyre Therapeutics has completed the pivotal Phase 3 trial for F351, a treatment for CHB-associated liver fibrosis, in China. Topline data is expected by Q1 2025.
The completion of a pivotal Phase 3 trial is a significant milestone for Gyre Therapeutics, indicating progress in their clinical development. The anticipation of topline data by Q1 2025 could generate investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100